Calgon Carbon Reactivation Study Shows Removal and Destruction of PFAS

Peer-reviewed journal article details Calgon Carbon study findings

Pittsburgh, PA, Dec. 06, 2022 (GLOBE NEWSWIRE) — A new study by Calgon Carbon Corporation (“Calgon Carbon”), a wholly owned subsidiary of Kuraray Co., Ltd. (TYO: 3405) (“Kuraray”), has provided a definitive response to a persistent question about the fate of PFAS during reactivation of activated carbon. Reactivation is a high temperature thermal process that is commonly used by municipalities and industrial users to recycle their used activated carbon and destroy contaminants it has removed.

“The single-biggest conclusion from the study is that PFAS compounds are effectively removed from spent carbon through the reactivation process, as well as showing greater than 99.99% destruction of PFAS through our furnace and abatement system,” explained Rebecca DiStefano, Senior Applications Engineer at Calgon Carbon.

Remediation-The Journal of Environmental Cleanup Costs, Technologies, & Techniques, featured the findings of Calgon Carbon’s study in a peer-reviewed article published in the autumn issue of the esteemed quarterly journal that focuses on the practical applications of remediation techniques and technologies.

“The data detailed in our article effectively demonstrated the removal of PFAS compounds from granular activated carbon (GAC) and greater than 99.99% destruction of PFAS compounds through the furnace and off-gas abatement system,” said DiStefano, the lead author of the Remediation article.

The study’s findings come at a time of growing concern and increased focus about the impact of PFAS, often referred to as “forever chemicals” because of their inability to break down over time in the environment.

“This is research that no one else in the industry has published.,” DiStefano said. “We don’t want to have these unknowns stay out there and linger in people’s minds. We wanted to answer these questions and move the industry forward and continue promoting GAC as the best available treatment (BAT) technology for removing PFAS.”

Calgon Carbon’s FILTRASORB® GAC, sourced from bituminous coal, has demonstrated superior PFAS-removal capabilities compared to other carbons for two decades.

GAC is the most widely used and well-established treatment technology for the removal of PFAS contaminants from drinking water and wastewater. Thermally treating GAC at the end of its useful service life – known as spent carbon – is called reactivation, a process that vaporizes and destroys adsorbed contaminants at extremely high temperatures and restores the GAC to a near-virgin state so it can be reused.

In the first stage of Calgon Carbon’s proprietary reactivation process, PFAS-laden GAC is heated in a furnace for several hours at temperatures of up to 1750 degrees Fahrenheit, imparting enough energy to break down PFAS’s carbon-fluoride bonds, the strongest in chemistry.

The off gas from the reactivation furnace then moves into an abatement system, which features a thermal oxidizer/afterburner designed to destroy any organics that were not destroyed in the furnace. From there, it proceeds through a scrubber to neutralize any acid gases, such as hydrogen fluoride, and remove them from the abatement air. Finally, it passes through a baghouse to eliminate particulate matter.

“It’s a combination of our reactivation furnaces and the abatement systems that achieves these very high levels of destruction,” said John Matthis, Global PFAS Team leader at Calgon Carbon. “With other technologies, you may be removing PFAS from the water, but the question is, what do you do with that media once it has PFAS on it? Activated carbon and reactivation are unique because not only are we removing the contaminants from your water, we also are effectively removing them from the carbon – and from the environment as well.”

For its study, Calgon Carbon enlisted the services of an independent, third-party vendor to test air samples for 36 PFAS compounds. Another third-party vendor analyzed well water and treated motive water samples for PFAS, as well as analyzing samples of spent carbon, reactivated carbon, abatement dust, and bicarbonate raw material for extraction and targeted PFAS.

Since creating the first activated carbon products from bituminous coal in the 1940s, Calgon Carbon has been a pioneer in developing high-performing granular activated carbon products for water purification.

Jenalle Brewer, Senior Vice President – Drinking Water, Innovative Carbon Tech & Global Business at Calgon Carbon said, “PFAS is portrayed in the media as a relatively recent problem. However, we’ve been offering treatment solutions for PFAS for more than 20 years. Our FILTRASORB activated carbon products help to ensure that ‘forever chemicals’ are forever no more. It’s a problem people thought they had to live with, but as our study has proven, they really don’t.”

To learn more about Calgon Carbon’s study and the FILTRASORB product, visit NoMorePFAS.com.

About Calgon Carbon
Calgon Carbon, a wholly-owned subsidiary of Kuraray Co., Ltd. (TYO: 3405) (Kuraray), is a global leader in the manufacture and/or distribution of innovative coal-, wood- and coconut-based activated carbon products – in granular, powdered, pelletized and cloth form – to meet the most challenging purification demands of customers throughout the world. Calgon Carbon provides purification solutions for more than 700 distinct applications, including drinking water, wastewater, pollution abatement, and a variety of industrial and commercial manufacturing processes. Headquartered in Pittsburgh, Pennsylvania, Calgon Carbon employs approximately 1640 people and operates 20 manufacturing, reactivation, innovation and equipment fabrication facilities in the U.S., Asia, and in Europe, where Calgon Carbon is known as Chemviron. Calgon Carbon was acquired by Kuraray in March of 2018.  With complementary products and services, the combined organization will continue to focus on providing the highest quality and most innovative activated carbon and filtration media products, equipment, and services to meet

Video Content

Amanda Lofty
Calgon Carbon Corporation
724-541-2658
amanda.lofty@kuraray.com

GlobeNewswire Distribution ID 8709420

Graid Technology and Liqid Announce Accelerated Data Protection for the World’s Fastest NVMe Flash

SupremeRAID™ SR-1010 delivers best-in-class data protection, maximum flexibility, and even greater performance from Liqid’s Honey Badger NVMe storage devices

Graid Technology & Liqid partner to deliver best-in-class NVMe data protection and performance

SANTA CLARA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — Graid Technology, the multi-award-winning data protection provider and developer of the only RAID card to deliver the full performance capability of NVMe SSDs, and Liqid, a leading provider of composable disaggregated infrastructure (CDI) and NVMe storage solutions, today announced a cooperative agreement to partner in customer engagements. The relationship will be focused on providing data protection along with elimination of I/O bottlenecks for customers deploying Liqid’s Honey Badger NVMe flash devices and CDI solutions.

“There is a tremendous amount of upside for both companies in this new relationship,” said Leander Yu, CEO and President of Graid Technology. “Liqid is a key player in both the NVMe storage and CDI market, and we are excited to be closely aligned with them and their partner community where together we will have an unbeatable combination.”

The flexibility and scalability of Liqid products provides the ideal platform to leverage the simplicity and scalability of the SupremeRAID™ SR-1010 offerings. The combination of Liqid and SupremeRAID™ by Graid Technology offers customers and partners a data protection option that drives a lower cost of deployment along with improved customer satisfaction and improved business continuity.

“Our partnership with Graid Technology helps customers extract added value from our LQD-4500 (Honey Badger) NVMe storage devices,” said Sumit Puri, CEO and cofounder, Liqid. “While the Honey Badger is already the world’s fastest SSD at 4M IOPS, when paired with SupremeRAID™ SR-1010, it delivers more than 5M IOPS with solid RAID 6 protection. SupremeRAID™ works brilliantly with the Honey Badger in both composed and non-composed deployments.”

SupremeRAID™ SR-1010 by Graid Technology is now included on Liqid’s hardware compatibility list and is available through many Liqid channel partners. Please contact Liqid to test-drive the Honey Badger with accelerated SupremeRAID™ protection for yourself.

About Graid Technology

Graid Technology is headquartered in Silicon Valley, California, with an office in Ontario, CA, and an R&D center in Taipei, Taiwan. Graid technology’s SupremeRAID™ performance is breaking world records as the first NVMe and NVMeoF RAID card to unlock the full potential of your SSD performance: a single SupremeRAID™ card delivers 19 million IOPS and 110GB/s of throughput. For more information, visit www.graidtech.com or connect with us on Twitter or LinkedIn.

About Liqid

LIQID Inc., headquartered in Broomfield, Colorado, is a pioneer in composable infrastructure. Freeing IT users from vendor lock-in and traditional purchasing cycles, Liqid enables them to build a living data center architecture that changes to meet their business needs and scales as needed. All of this while offering powerful improvements in data performance, architectural optimization, hardware disaggregation, and footprint efficiency. For more info: www.liqid.com.

Additional Resources

Contact Information:
Andrea Eaken
Graid Technology Director of Marketing & Media Relations
andrea.eaken@graidtech.com

Robert Brumfield
Liqid Sr. Director, Global Communications
robert.brumfield@liqid.com

Related Files

SupremeRAID SR-1010 for PCIe 4.pdf

Related Images

Image 1: Graid Technology & Liqid partner to deliver best-in-class NVMe data protection and performance

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8708889

Nucleus Software Implements Digital Lending Solution to Bank of Sydney, Empowering a Shift Towards Digital Customer Experience

The solution allows the bank to deliver faster credit decisions and automate workflows, enhancing business agility and productivity.

SYDNEY, Dec. 06, 2022 (GLOBE NEWSWIRE) — Nucleus Software transforms Bank of Sydney towards digital customer experience with FinnOne neo™ solution. Bank of Sydney is an organization committed to providing genuine value for its people, customers, communities, and partners. To deliver responsible and sustainable growth, the bank has a clear strategy that’s supported by technological transformation. Core strategic initiatives which focus on driving efficiency and effectiveness, with an emphasis on automation, building workflows and digitizing processes across the business have significantly enhanced the banking experience for both the Bank’s customers and employees.

Through the digital lending platform FinnOne neo™ from Nucleus Software, Bank of Sydney will be able to provide an improved customer experience with a faster approval process and communications. By employing the platform’s real-time dashboard for tracking and reporting, the bank aims to enhance both the internal and external transparency, and accountability of its processes.

CEO of the Bank of Sydney, Mr. Miltos Michaelas, was delighted by the progress and said, “By adopting a plug & play platform like that of FinnOne neo™ from Nucleus Software, Bank of Sydney is enabled to deliver faster and more efficient services in a seamless manner. There is a growing need for integration with various sources of data for swift and precise application on-boarding and decision-making in the Financial Services Industry. FinnOne neo™ provides the capability to integrate with third-party systems to collect, combine, and use data for all of Bank of Sydney’s lending requirements.”

Mr. Parag Bhise, CEO of Nucleus Software, was also pleased to state that “Our lending platform is highly configurable, thus removing the need to create a new expensive and complex system from scratch. We expect that the deployment of our FinnOne neo™ platform will further empower Bank of Sydney to improve banking experiences for their customers”.

With successful and smooth go-live of the new platform, many Bank of Sydney applications are now processed through FinnOne neo™. The adoption of the platform establishes a strong foundation for further integration and growth for the Bank.

About Bank of Sydney: For more information, please visit: www.banksyd.com.au

About Nucleus Software:

Nucleus Software Exports Ltd. is a publicly traded (BSE: 531209, NSE: NUCLEUS), software product company that provides lending, transaction banking products to global financial leaders.

Nucleus Software powers the operations of 200+ Financial Institutions across 50+ countries, supporting retail and corporate lending, cash management, mobile and internet banking. Its products facilitate 26+ million transactions/day, managing over US $ 200 billion of loans and enabling 300,000+ daily users.

Nucleus Software’s flagship products, built on the latest technology:

  • FinnOne neo™: Next-generation digital lending solution, built on an advanced technology platform.
  • FinnAxia™: An integrated global transaction banking solution used by banks worldwide.
  • PaySe™: World’s first online & offline digital payment solution created to democratize money.

For more information, please visit: http://www.nucleussoftware.com

Contact Information:
Deepika Gulabani
marcom@nucleussoftware.com
+91-9289708877

This content was issued through the press release distribution service at Newswire.com.

GlobeNewswire Distribution ID 8709321

Acronis #CyberFit Summit 2022 Gathered 1,000+ MSPs, CISOs and more, at Exciting Knowledge-sharing Event

Magic Johnson and Judge Louis Freeh spoke at Acronis Summit 2022

Magic Johnson and Judge Louis Freeh spoke at Acronis Summit 2022

At this year’s #CyberFit Summit, Acronis rolled out the red carpet for insightful speakers and announced two new products along with the promotion of the company’s new chief sales officer.

BURLINGTON, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) — Coming out of #CyberFit Summit 2022, Acronis, the global leader in Cyber Protection, is poised for exciting developments in cybersecurity in the new year. In front of more than 1,000 attendees, 50 journalists and 100 speakers, Acronis unveiled the upcoming releases of Acronis Advanced Automation and Acronis Advanced Security + EDR, and introduced the newest member of the c-suite, Chief Sales Officer Katya Ivanova.

Through superstar keynotes, expert panels, and hands-on workshops, MSPs and IT professionals were left with deeper insights into the threat landscape, new business-building tips and a path to accelerate growth while securing customer loyalty.

Acronis CEO Patrick Pulvermueller kicked off the three-day event in Miami Beach with his keynote. He opened with staggering statistics illustrating the enormity of data today. There are currently 10 million physical servers on Earth, and data creation has increased 90-fold just since 2010. To protect this sheer enormity of data, consolidation and simplification are the future. Pulvermueller tied in the tagline of #CyberFit Summit – cyber protect the future – and emphasized Acronis’ unwavering focus on partner success, innovation and simplification.

“The continuous rise of cyber protection the defining moment of our industry,” said Patrick Pulvermueller, CEO at Acronis. “During our #CyberFit Summit, we were thrilled to share our vision for Acronis and how cyber protection will evolve in the year ahead. At Acronis, we’re continuing to set our partners and customers up for success.”

In multiple sessions at the Acronis #CyberFit Summit in Miami, cybersecurity analysts and experts provided an inside look at how cyberattacks attacks work, how MSPs are impacted and how Acronis Cyber Protection Solutions prevent them. Other notable keynotes from the event included former FBI Director, Judge Louis Freeh talking about his experience with the mafia and ransomware; basketball legend and serial entrepreneur, Earvin “Magic” Johnson, giving an inspirational speech on how he has parlayed the skills and tenacity acquired on the court into a winning formula for his successful business ventures; Acronis founder and Chief Research Officer Serg Bell’s discussion about expanding the future of MSPs; and the #CyberWomen keynote, where several influential women speculated on the bright future for women in the cyber field.

#CyberFit Summit sponsors Silvereye Technologies and Galactic Advisors were thrilled to be part of the event. “A decade ago, excellent cybersecurity and data protection was a luxury. Now that ransom payments are skyrocketing, companies are suffering huge hits, not only financially but also to their reputation. Cybersecurity is now a necessity,” said Jennifer Pierce at Galactic Advisors. “Events like #CyberFit Summit are an excellent opportunity to share knowledge and position our partners to make a significant positive impact in their communities around the world.”

Cameron May, Chief Strategist of Silvereye Technologies, added, “The Acronis Platform is a cornerstone for cybersecurity. The Acronis Summit combines a wide range of technologies, industry leaders and strategists together for what Silvereye views as the most important event of the year.”

MSPs, CISOs, CIOs and architects left #CyberFit Summit laden with bursting camera reels (more than 8,000 photos were taken over the three days), with great new ideas and with excitement for the Acronis developments to come in early 2023. Perhaps, attendees also returned home with a need to rest their feet: the average conference attendee walked 25,000 each day. Now, that’s #CyberFit.

To learn more about the Acronis #CyberFit Summit and register for next year’s event taking place October 16 – 18, 2023 in Miami Beach, Florida, visit: https://promo.acronis.com/summit-2023-pre-register.html.

About Acronis
Acronis unifies data protection and cybersecurity to deliver integrated, automated cyber protection that solves the safety, accessibility, privacy, authenticity, and security (SAPAS) challenges of the modern digital world. With flexible deployment models that fit the demands of service providers and IT professionals, Acronis provides superior cyber protection for data, applications, and systems with innovative next-generation antivirus, backup, disaster recovery, and endpoint protection management solutions powered by AI. With advanced anti-malware powered by cutting-edge machine intelligence and blockchain based data authentication technologies, Acronis protects any environment – from cloud to hybrid to on premises – at a low and predictable cost.

Founded in Singapore in 2003 and incorporated in Switzerland in 2008, Acronis now has more than 2,200 employees in 40 locations in 19 countries. Acronis Cyber Protect solution is available in 26 languages in over 150 countries and is used by over 20,000 service providers to protect over 750,000 businesses.

Press contacts:

Karl Bateson

Global Director PR & Communications
Karl.Bateson@acronis.com

A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3407d1d8-e41f-431b-8735-ea28f963effe

GlobeNewswire Distribution ID 8708767

TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

  • Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer’s disease (AD) patients
  • TB006 also demonstrated improvements in PET and MR imaging, consistent with dissolution of toxic amyloid plaque shown in preclinical studies
  • Ongoing open-label extension study with more than 100 participants is generating long-term safety and efficacy data

FOSTER CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — TrueBinding Inc. a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases and other serious diseases, highlighted the unique method of action (MOA) of TB006, an investigational monoclonal antibody against Galectin-3 (Gal-3) for the treatment of mild to severe AD, at the recent 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.

Aβ, p-Tau and other pathogenic factors are not considered toxic when they exist as monomers; however, when they are aggregated and become oligomers, they become very toxic, which leads to neuronal death and neuroinflammation. Gal-3 has been shown to play a detrimental role in AD pathology by promoting the aggregation of Aβ, p-Tau, Apo-E4 and other pathogenic factors. In preclinical studies, TB006, a humanized monoclonal antibody, was shown to block Gal-3 and dissolve the toxic aggregates, which reversed disease progress in animal models of AD.

“Our monoclonal antibody, TB006, targets Gal-3, which acts as a glue and has a role in the formation of toxic protein oligomers that compromise normal neuronal function in the brain and leads to disease progression,” said Dongxu Sun, Ph.D., chief executive officer of TrueBinding. “Unlike other antibodies in development that target the components of the aggregates, TB006 is unique in that it targets what may be the key nucleating factor for the aggregates to inhibit its activity. We are encouraged by the early clinical data and look forward to advancing our understanding of TB006 and its potential to improve cognition and functioning with an ambitious goal of potentially reversing the course of AD.”

Dr. Sun continued, “Our Phase 1b/2 proof-of-concept trial demonstrated the potential of TB006 to improve cognition and function in patients with Alzheimer’s disease with a short one-month weekly treatment regimen. Improvements in patient cognition and function were seen as early as 15 days after the first treatment, and continued through day 36, only diminishing once we stopped treatment with TB006. Notably, this efficacy was observed across the patient population, whose disease severity ranged from mild to severe. Beyond the quantitative clinical measures we track, we’ve also received an overwhelming number of touching personal stories from participating physicians and caregivers about the dramatic improvement in symptoms of trial participants and the hope they have for a safe and effective treatment for this debilitating disease.”

“There is an immense need for disease modifying treatments that can help the more than 6.5 million patients diagnosed with Alzheimer’s disease in the U.S,” said Malisa Agard, MD, principal investigator, Conquest Research. “Unfortunately, our existing treatment options are quite limited, so I was excited to review the data from the TB006 trial. Despite it being early-stage data, it gives me a great deal of hope in the potential of TB006 to help the millions of patients who are suffering now and, additionally, the millions more who are likely to develop this disease in the future.”

Data from the Phase 1b/2 trial presented at CTAD and more information on the promising mechanism of action of novel antibody TB006 can be found on the TrueBinding website at www.truebinding.com.

In the Phase 1b/2 trial, administration of TB006 versus placebo reduced the Clinical Dementia Rating-Sum of Boxes (CDR-SB*) score, a patient and caregiver combined assessment, after just one month treatment. Through day 104, the data showed a treatment difference of 63 percent versus placebo, which represents a score change of -0.44 points (p=0.08); indicating a trend toward improvement in clinical function of patients in the analysis of the Intent-to-treat (ITT) population. Of note, at Day 36 TB006 versus placebo significantly improved not only Mini Mental State Examination (MMSE**) scores by 1.02 points (p=0.02), but also the percentage of responders (one or more points reduction of CDR-SB from the baseline, p=0.016). In addition, treatment with TB006 resulted in patient improvements across a range of disease severity, including within the difficult-to-treat moderate and severe patient population. In addition, TB006 significantly reduced Aβ 42 plasma levels and reduced amyloid plaques, further evidence of an impact on the underlying disease.

TB006 was safe and well tolerated through the observation period of 3.5 months. There were no treatment-related serious adverse events and no imaging-related abnormalities (ARIA). The most common adverse event (AE) was infusion reaction.

The trial was a seamless Phase 1b/2 double-blinded, placebo controlled, multicenter study conducted at 15 active sites in the U.S. to assess the safety and short-term efficacy of TB006 in 157 patients with mild to severe AD. Patients who met clinical diagnostic criteria for AD and had a screening MMSE <24 with no confounding neurologic or psychiatric disease were eligible. Amyloid positivity was not required for study participation. In the Phase 1b portion, three groups (140 mg, 420 mg, 1,000 mg) of eight patients received either weekly TB006 or placebo infusions in sequential ascending fashion for one month. In the Phase 2 portion, participants were randomized (1:1) to receive either TB006 (1,000 mg) or placebo weekly for one month. Other endpoints were the MMSE, neuropsychiatric inventory (NPI), CDR battery and plasma and imaging (MRI/PET) biomarkers. Cognition testing was performed at baseline and on days 15, 36, 64 and 104. Safety assessments were conducted at each visit.

An ongoing open-label extension study assessing monthly injections of TB006 at 4,000 mg in over 100 participants is generating long-term safety and efficacy data, with initial, interim data expected in the first quarter of 2023. A longer-term, 12-month, randomized, placebo-controlled Phase 2b trial is planned.

* CDR-SB is a numeric scale used to quantify the various severity of symptoms of dementia. Based on interviews of people living with AD and family/caregivers, qualified healthcare professionals assess cognitive and functional performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The total score of the six areas is the score of CDR-SB, and CDR-SB is also used as an appropriate item for evaluating the effectiveness of therapeutic drugs targeting the early stages of AD.

**The Mini Mental State Examination (MMSE) is a tool that can be used to systematically and thoroughly assess mental status. It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language.

About Alzheimer’s Disease
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative brain disorder. AD is the leading cause of dementia among older adults, affecting as many as 55 million patients worldwide1 with an incidence expected to increase as the global population ages. AD is a type of dementia that begins with mild memory loss but eventually symptoms can become severe enough to affect other cognitive abilities that are required for daily living.

Major pathological hallmarks of AD include the formation of toxic oligomers in the brain involving the major proteins: amyloid beta (Aβ) peptides and phospho-tau, alpha synuclein, and ApoE4. Galectin-3 (Gal-3), an endogenous protein that is found at abnormally high levels in the brains of AD patients, has been shown to play a key role in AD pathology.2 Gal-3 is involved in the sustained release of proinflammatory molecules, such as cytokines and chemokines which contribute to the toxic environment in the brain that drives the progression of AD2. Gal-3 binds to Aβ peptides, p-Tau and other amyloid proteins, and acts as a glue, causing these proteins, which normally exist as monomers, to bind and form toxic oligomers. These oligomers cause plaque deposits in the brain, inflammation, and direct toxicity to intact neurons; thereby resulting in cognition defect symptoms in AD patients. While there is currently no known cure for AD, Gal-3 inhibition may provide a multi-pronged approach to the treatment of AD.

About TB006
TB006 is a humanized monoclonal antibody that, based on preclinical data and early clinical studies, has the potential to improve cognition and functioning of patients with Alzheimer’s disease (AD). In pre-clinical evaluations, Galectin-3 was shown to intrinsically promote the aggregation of Aβ and pTau proteins. In AD in vivo model studies, TB006 showed promising capabilities in significant reduction of the aggregation of Aβ/Tau proteins and neuroinflammation, and significant improvement of cognitive performance, which show potential therapeutic effect of TB006 in addressing underlying pathology and ameliorating the course of AD. Human safety of TB006 was established in a single, escalating dose safety and tolerability study, where doses of up to 5000 mg were safe and well tolerated. In a Phase 1b/2 proof-of-concept trial in mild to severe AD patients, TB006 demonstrated statistically significant improvements in cognition and functioning. TB006 is currently being evaluated in a Phase 2 open-label extension trial in patients with AD and in a Phase 2 trial in patients with acute ischemic stroke.

About TrueBinding, Inc.
TrueBinding Inc. is a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases, including Alzheimer’s disease (AD), as well as stroke, oncology and other serious diseases. The company is focused on rapidly advancing its lead drug candidate, TB006, a humanized monoclonal antibody targeting Galectin-3, that is being evaluated in a Phase 2 open-label extension trial in patients with AD and in a Phase 2 trial in patients with acute ischemic stroke. For more information, visit www.truebinding.com.

Contacts:

Dongxu Sun, PhD
Chief Executive Officer
dsun@truebinding.com
650.847.1117

References:

  1. World Health Organization . Geneva, Switzerland: World Health Organization; 2021. Fact sheets of dementia [Internet] [cited 2022 Apr 13]. Available from: https:// www.who.int/news-room/fact-sheets/detail/dementia.
  2. Boza-Serrano, A., Ruiz, R., Sanchez-Varo, R. et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019; 138:251–273. DOI:10.1007/s00401-019-02013-z https://pubmed.ncbi.nlm.nih.gov/31006066/

GlobeNewswire Distribution ID 8708878

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Jeito Capital strengthens its support in Pulmocide with participation in

$52 million financing

The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole

Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, announced today its participation in a $52 million Series C extension financing round in portfolio company Pulmocide, a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases. Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.

Jeito participated in the extension alongside new lead investors, Pictet Alternative Advisors and Vivo Capital together with other existing investors, SV Health Investors, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc., Adjuvant Capital, Asahi Kasei Pharma, Longwood Fund, and the Cystic Fibrosis Foundation. The total raise for Pulmocide’s Series C is $147.5 million.

Proceeds from the financing will be used to further fund clinical development, manufacturing scale-up and preparation for potential commercialization of the company’s lead product candidate, opelconazole. Opelconazole is a potent, novel inhaled triazole antifungal being developed for the treatment of invasive pulmonary aspergillosis (IPA), a disease associated with high mortality and morbidity. The Company has initiated a global registration program to test the compound when given in addition to current standard of care against invasive pulmonary aspergillosis in patients failing first line therapy. Pulmocide is also conducting a Phase 2b clinical trial using opelconazole as a monotherapy for prophylaxis against aspergillus infections in patients post lung transplant surgery.

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented: “Pulmocide, our fourth investment, has made significant clinical and regulatory progress since our involvement, and the team continues to accelerate the development of its registration-stage lead product with the aim of delivering a promising new therapy to patients as quickly and safely as possible.”

Sabine Dandiguian, Managing Partner at Jeito, said: Pulmocide continues to make remarkable headway in the field of severe respiratory disease, and opelconazole has the potential to deliver a transformative therapeutic option for patients resisting to existing treatments. Jeito’s further investment in Pulmocide demonstrates our commitment to support the most innovative biopharmaceutical companies and accelerate the development of much-needed treatments for patients. We look forward to continuing our work with Daniel and the team.”

Daniel Burgess, Chairman and CEO of Pulmocide. “We are thrilled with the support from both our new and existing investors in advancing Pulmocide’s missionTogether with the $95 million raised last year, we are well positioned to move opelconazole through late-stage development and to prepare to bring this potentially important new therapy to patients desperately in need of new treatment options.”

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

@Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn.
About Pulmocide

Pulmocide Ltd (www.pulmocide.com) is a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients at risk of developing serious complications associated with aspergillosis, such as immunocompromised patients and those with severe pulmonary diseases. The company is currently focused on acute and chronic treatments for pulmonary aspergillosis and its lead product opelconazole is being developed initially for the treatment of IPA.

About Pulmonary Aspergillosis

The incidence of pulmonary fungal disease has increased substantially over the past two decades with Aspergillus species being the most common pathogen. Invasive pulmonary aspergillosis (IPA) is associated with high morbidity and mortality rates in immuno-compromised patients including those undergoing hematological stem cell or solid organ transplantation (particularly lung transplants) and some patients in critical care, including those with COVID-19-associated pulmonary aspergillosis. Aspergillus infection also plays an important role in severe asthma and cystic fibrosis and has been correlated with poorer clinical outcomes in patients with chronic obstructive pulmonary disease. Chronic lung infections with Aspergillus can leave patients with extensive and permanent lung damage, requiring a lifetime of antifungal treatment.

About Opelconazole

Pulmocide’s opelconazole is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure. This profile is anticipated to enhance efficacy with a low risk for adding to the toxicities and drug-drug interactions seen with systemic antifungal therapies. Under the United Kingdom’s Special Needs provision, opelconazole was found to be generally well tolerated and demonstrated remarkable clinical responses. In this program, patients with a variety of different clinical profiles that had failed previous antifungal treatment options responded well when opelconazole was added to their treatment regimen. Opelconazole has the potential to be useful in a variety of conditions where Aspergillus has been implicated, including chronic pulmonary aspergillosis, cystic fibrosis, severe asthma, allergic bronchopulmonary aspergillosis, chronic pulmonary obstructive disease, severe flu, and post-COVID-19-associated lung damage. A late-stage clinical program has been initiated to support registration in patients who have failed prior therapy for IPA.

For further information please contact :

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, EA
assia@jeito.life
Tel : +33 6 76 49 37 94

Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam / Lucie Foster
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700

Marion Bougeard
marion@achto-conseil.fr
Tel : +33 6 76 73 57 31

GlobeNewswire Distribution ID 1000770716